This conclusion is further supported by our previous observation that basal expression of EGFR can be detected in 100% and activated EGFR (pEGFR) in 55% of CTCs from HNSCC patients with locally advanced stage disease [25]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.